Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.76), $0.09 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $12.45 million versus the consensus estimate of $11.84 million.

“2020 was a transformational year for our company with the launch of our first product, CAPLYTA. I am proud of the important progress that our organization has achieved. We navigated unprecedented and challenging COVID-19 circumstances and still accomplished key commercial and clinical development milestones,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We look forward to continuing our progress as we seek to expand our CAPLYTA label to include patients with bipolar depression. We are excited about our late-stage lumateperone programs in depressive disorders and the advancement of a long-acting injectable formulation into clinical trials as well as further expanding our pipeline with ITI-1284.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.